Jupiter Neurosciences Net Cash Flow 2023-2025 | JUNS

Jupiter Neurosciences net cash flow from 2023 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Jupiter Neurosciences Net Cash Flow 2023-2025 | JUNS

Jupiter Neurosciences net cash flow from 2023 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$70B
Zoetis (ZTS)$68.3B
Takeda Pharmaceutical (TAK)$47.7B
Daiichi Sankyo, - (DSNKY)$47.6B
BeOne Medicines - (ONC)$35.2B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$19.8B
Merck (MKKGY)$17.1B
Shionogi (SGIOY)$15.2B
United Therapeutics (UTHR)$14.1B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.6B
Madrigal Pharmaceuticals (MDGL)$8.2B
Corcept Therapeutics (CORT)$7.6B
Grifols, S.A (GRFS)$7.4B
Ionis Pharmaceuticals (IONS)$7B
Stevanato Group S.p.A (STVN)$6.9B
Hikma Pharmaceuticals Plc (HKMPF)$5.3B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$3.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.4B
Ocular Therapeutix (OCUL)$2.2B
Endo (NDOI)$1.8B
Dyne Therapeutics (DYN)$1.8B